Physician profile
Diane Smith Annalett
NPI 1548277643
$11,967.40
in general payments reported to CMS, 2019-2025
27 companies · $2,072 in 2025
The $2,072 reported for 2025 was more than what 88% of Geriatric Psychiatry providers received nationally (typical 2025 total: $125).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $280 · 2020: $1,231 · 2021: $2,070 · 2022: $2,506 · 2023: $1,742 · 2024: $2,067 · 2025: $2,072.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,818 · Education: $63.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,817.58 |
| Education | $63.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,681.21 | 2020-2025 | Caplyta |
| Abbvie INC. | $1,519.04 | 2021-2025 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $1,202.16 | 2019-2025 | Austedo Xr, Uzedy, Austedo |
| Neurocrine Biosciences, INC. | $993.80 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $931.25 | 2019-2025 | Rexulti |
| Alkermes, INC. | $751.80 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Vanda Pharmaceuticals INC. | $682.33 | 2019-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $644.13 | 2020-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $559.16 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $531.59 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $465.83 | 2021-2025 | Spravato |
| Bausch Health US, LLC | $389.55 | 2020-2025 | Aplenzin, Wellbutrin |
| Almatica Pharma LLC | $330.83 | 2021-2025 | Loreev Xr |
| Allergan, INC. | $246.71 | 2019-2020 | |
| Axsome Therapeutics, INC. | $202.60 | 2022-2025 | Auvelity, Sunosi |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $140.13 | 2023-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $134.73 | 2022-2025 | Qelbree |
| Biogen, INC. | $103.65 | 2022-2023 | |
| Indivior INC. | $89.79 | 2022-2023 | Sublocade |
| E.R. Squibb & Sons, L.L.C. | $82.52 | 2024-2025 | Cobenfy |
| Gilead Sciences, INC. | $77.41 | 2021 | |
| Eisai INC. | $53.89 | 2020-2022 | |
| Alfasigma USA, INC. | $44.27 | 2022 | |
| Noven Therapeutics, LLC | $40.72 | 2024 | Xelstrym, Secuado |
| Avanir Pharmaceuticals, INC. | $27.87 | 2022 | |
| Luye Pharma (USA) Ltd. | $24.52 | 2025 | Erzofri Extended-Release |
| Orexo US, INC. | $15.91 | 2023 | Zubsolv |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diane Annalett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.